HARMONY: a € 40 million PROJECT FOR BETTER CARE OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES
LATEST UPDATE – London – November 23/24, 2017
On 23 and 24 November 2017 the HARMONY Alliance organized a workshop on the definition of meaningful outcomes for hematological malignancies.
We were invited as patients advocates, together with 60 stakeholders to discuss outcomes relevant to all stakeholders across all haematological malignancies.
#patient #advocates at our #hmoutcomes workshop. Through its Stakeholder Forum, HARMONY will collect input from #patientorganizations have an important role in meeting @HarmonynetEU goals and ambitions @IMI_JU @EFPIA pic.twitter.com/34uT7x9LqW
— Harmony Alliance (@HarmonynetEU) November 23, 2017
Our good friend Tamas has a lot of excellent material available for patient advocates. Take a look if you don't yet know his work.
Nice chap as they say in London 😉 https://t.co/TW7u5NoJkH
— MDS Alliance (@HeretoHelpMDS) November 23, 2017
— Tamas Bereczky (@tamasbereczky) November 18, 2017
HARMONY in action and looking forward to discussions with our valued #stakeholders workshop meaningful #outcomes for #hematological #malignancies at @IMI_JU @BD4BO @EFPIA @jangeissler @Bayer @TakedaOncology @ChariteBerlin @Celgene @Celgene_Myeloma @TakedaPharma @patvocates pic.twitter.com/SulGJrTp3h
— Harmony Alliance (@HarmonynetEU) November 23, 2017
Brussels/Salamanca – January 9, 2017
The Innovative Medicines Initiative (IMI) has approved HARMONY, a project that aims to foster better access and care for patients with various hematologic malignancies (HM) with the use of big data. The project is made up of 51 partners from 11 European countries, including 7 pharmaceutical companies.
Other organisations such as Myeloma Patients Europe (MPE), Lymphoma Coalition, MDS Alliance and CLL Advocate will be involved in this project as well in order to provide the patient perspective.
MDS Alliance will attend the kick-off meeting in mid-January 2017, together with the other patient advocacy groups and all stake-holders.
More news to follow soon.
INNOVATIVE MEDICINES INITIATIVE APPROVES
€ 40 million PROJECT FOR BETTER CARE OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES
Brussels/Salamanca, January 9, 2017. The Innovative Medicines Initiative (IMI) has approved HARMONY, a project that aims to foster better access and care for patients with various hematologic malignancies (HM) with the use of big data. The project is made up of 51 partners from 11 European countries, including 7 pharmaceutical companies.
HARMONY will capture, integrate, analyze and harmonize anonymous patient data from high-quality multidisciplinary sources to unlock valuable knowledge on multiple myeloma (MM), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma (NHL), myelodysplastic syndromes (MDS) and pediatric HMs.
Building on pre-existing, long-lasting collaborations between Academic institutes and the pharmaceutical industry, the HARMONY project shall further advance HM management through a more efficient process of treatment development and rapid decision-making. The expected outcome will be better prognosis and quicker life-saving decisions, important for patients suffering from these hematological diseases.
The project brings together key stakeholders in the clinical, academic, patient, HTA (health technology assessment), regulatory, economical, ethical and pharmaceutical fields to:
- Developing a data sharing platform that empowers clinicians and policy stakeholders to improve decision-making
- Establishing a network reflecting the European HMs landscape
- Defining clinical endpoints and standard outcomes in ALL (paediatric & adult), NHL, MM, AML, CLL, MDS
- Alignment of key stakeholders on relevance of these outcomes (policy makers, payers, patients)
- Providing means for analysing complex data sets comprising different layers of information
- Identifying specific markers for early registration of innovative and effective therapies for HMs
The HARMONY project’s final deliverable is a big data platform which integrates outcome measures and endpoint definitions for HMs. HARMONY will achieve this from a pan-European perspective by uniting and aligning European stakeholders and key opinion leaders in the field. The 5-year project will start in January 2017 and is funded through the Innovative Medicines Initiative (IMI); Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Harmony is coordinated by two public leads: Prof. Dr. Jesús Marïa Hernández from Instituto de Investigación Biomédica de Salamanca, Spain, and Dr. Guillermo Sanz from Instituto de Investigación Sanitaria del Hospital La Fe de Valencia, Spain, and by two EFPIA leads, Tayyab Salimullah from Novartis Oncology and Pam Bacon from Celgene International.
Contact information: Harmonyoffice@ibsal.es
THE INNOVATIVE MEDICINES INITIATIVE
The Innovative Medicines Initiative (IMI) is Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.
It should be made clear in the text and layout that the communication reflects the author’s view and that neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.
Partners in HARMONY
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Spain
- Instituto de Investigación Sanitaria del Hospital La Fe de Valencia (HULAFE), Spain
- Celgene International II SARL, Switzerland
- Novartis, Switzerland
- Synapse Research Management Partners, S.L. (SYNAPSE), Spain
- Universitaet Ulm (UULM), Germany*
- Alma Mater Studiorum – Università di Bologna (UNIBO), Italy*
- European Hematology Association (EHA), The Netherlands*
- ELN Foundation (ELN), Germany*
- GMV Soluciones Globales Internet S.A.U. (GMV), Spain*
- European Alliance for Personalised Medicine (EAPM), Belgium
- Medizinische Universitaet – Wien (MUW), Austria*
- Erasmus Universiteit Medisch Centrum Rotterdam (EMC), The Netherlands
- University of Navarra (UNAV), Spain
- Università degli Studi di Torino (UNITO), Italy
- Stichting VUmc, The Netherlands
- The Chancellor, Masters and Scholars of the University of Cambridge (UCAM), United Kingdom
- University of Rome ‘Tor Vergata’ (URTV), Italy
- Goethe University Frankfurt (GUF), Germany
- Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL), France
- Jose Carreras Leukaemia Research Institute (IJC), Spain
- European Research Initiative on CLL e.v. (ERIC), Germany
- Masaryk University (MU), Czech Republic
- Fundacio privada Institut D’investigacio Oncologica de Vall-Hebron (VHIO), Spain
- The Lymphoma Scientific Association (LYSA), France
- Ludwig-Maximilians-Universitaet – Muenchen (LMU-Muenchen), Germany
- Barts Health NHS Trust (BHT), United Kingdom
- Groupe Francophone des Myélodysplasies (GFM), France
- Heinrich-Heine-Universitaet – Duesseldorf (UDUS), Germany
- Fondazione Italiana per lo studio delle sindromi mielodisplastiche onlus (FISMonlus), Italy
- University of Newcastle upon Tyne (UNEW), United Kingdom
- German Society of Pediatric Oncology-Hematology GmbH gemeinnützig (GPOH), Germany
- Ospedale Pediatrico Bambino Gesù (OPBG), Italy
- University of York (UoY), United Kingdom
- European Organisation for Research and Treatment of Cancer (EORTC), Belgium
- European Society for Blood and Marrow Transplantation (EBMT), The Netherlands
- Flanders Institute of Biotechnology (VIB), Belgium
- University of Helsinki (UH), Finland
- Assistance Publique – Hôpitaux de Paris (AP-HP), France
- Genome Research Limited (GRL-SANGER), United Kingdom
- MediSapiens Ltd (MS), Finland
- MLL Munich Leukemia Laboratory GmbH (MLL), Germany
- LeukaNET (LeNET), Germany*
- National Institute for Health and Care Excellence (NICE), United Kingdom
- Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Spain
- Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), Germany
- Amgen, United Kingdom*
- Janssen Pharmaceutica NV, Belgium*
- Bayer Aktiengesellschaft, Germany*
- Menarini Ricerche S.p.A., Italy*
- Takeda, United Kingdom*
*Work package leaders and co-leaders
To view and download this news release Click Here